PharmaVentures conducted a compound valuation (bottom-up and bench marking using PharmaDeals Agreement s® data) providing the basis for future negotiations. PharmaVentures also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month PharmaVentures’ transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.

PharmaVentures managed the exchange of Confidential Disclosure Agreements followed by the facilitation of meetings leading to the exchange of confidential data presentations. PharmaVentures also set up and managed a confidential data room.

PharmaVentures designed a study combining primary and secondary research to assess unmet medical needs that the core technology could service as well as map out the competitive landscape in R&D to see the expected market shares of competitors and the clients potential products.

With the research highlighting key drivers for new technologies, PharmaVentures selected 15 product opportunities for in-licensing or in-house development with detailed evaluation of probable risks and returns.